Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis

Bone Marrow Transplant. 2015 Nov;50(11):1486. doi: 10.1038/bmt.2015.185. Epub 2015 Aug 17.

Authors

C Minoia¹, G Pisapia¹, G Palazzo¹, C Ingrosso¹, M Buonanno¹, C Spinosa¹, A Prudenzano¹, G Pricolo¹, P Mazza¹

Affiliation

¹ Haematology Unit and BMT, 'San Giuseppe Moscati' Hospital, Taranto, Italy.

PMID: 26281030
DOI: 10.1038/bmt.2015.185

No abstract available

Publication types

Evaluation Study
Letter

MeSH terms

Aged
Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / therapeutic use*
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bortezomib / administration & dosage
Bortezomib / therapeutic use*
Cyclophosphamide / pharmacology
Female
Filgrastim
Granulocyte Colony-Stimulating Factor / pharmacology
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation*
Humans
Interferon-alpha / administration & dosage
Male
Multiple Myeloma / drug therapy
Multiple Myeloma / therapy*
Polyethylene Glycols
Proteasome Inhibitors / administration & dosage
Proteasome Inhibitors / therapeutic use*
Recombinant Proteins / pharmacology
Remission Induction
Retrospective Studies
Thalidomide / administration & dosage
Thalidomide / therapeutic use*
Transplantation Conditioning
Transplantation, Autologous
Treatment Outcome

Substances

Angiogenesis Inhibitors
Antineoplastic Agents
Interferon-alpha
Proteasome Inhibitors
Recombinant Proteins
Granulocyte Colony-Stimulating Factor
pegfilgrastim
Polyethylene Glycols
Thalidomide
Bortezomib
Cyclophosphamide
Filgrastim